Showing 1 - 10 of 21
Persistent link: https://www.econbiz.de/10002019954
Background: Breast cancer (BC) is largely prevalent worldwide. HER2-positive BC account for roughly 20-25% of all BC cases and has an overall survival lower than other BC. Innovation on BC therapeutics is a constant, but novel therapies have higher costs. Therefore, cost-effectiveness research...
Persistent link: https://www.econbiz.de/10014489917
Persistent link: https://www.econbiz.de/10003675827
Persistent link: https://www.econbiz.de/10003857725
Persistent link: https://www.econbiz.de/10009301224
Persistent link: https://www.econbiz.de/10009301244
Persistent link: https://www.econbiz.de/10010350475
Persistent link: https://www.econbiz.de/10003841080
Background: Breast cancer (BC) is largely prevalent worldwide. HER2-positive BC account for roughly 20-25% of all BC cases and has an overall survival lower than other BC. Innovation on BC therapeutics is a constant, but novel therapies have higher costs. Therefore, cost-effectiveness research...
Persistent link: https://www.econbiz.de/10012648637
Persistent link: https://www.econbiz.de/10011825660